ArticleCentral-European journal of immunology2018
Neutralizing TGF-β promotes anti-tumor immunity of dendritic cells against pancreatic cancer by regulating T lymphocytes.
Article in Central-European journal of immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Single-cell RNA sequencing uncovers an immunosuppressive program in PDAC mast cells: tumour-driven activation, proliferation, and association with Treg recruitment.Annals of medicine · 2026Article
- The evolution of cellular-based immunotherapy in the treatment of gastric cancer: an overview of clinical trials.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Research progress on the influence of tumor microenvironment on immunotherapy for pancreatic ductal adenocarcinoma.Open medicine (Warsaw, Poland) · 2026Review
- Tumor Stroma as a Therapeutic Target for Pancreatic Ductal Adenocarcinoma.Biomolecules & therapeutics · 2024Review
- Transforming growth factor-β signaling: from tumor microenvironment to anticancer therapy.Exploration of targeted anti-tumor therapy · 2023Review
- Exploring the key genetic association between chronic pancreatitis and pancreatic ductal adenocarcinoma through integrated bioinformatics.Frontiers in genetics · 2023Article
- Targeting TGF-β signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction.Frontiers in cell and developmental biology · 2022Review
- Dilemma and Challenge of Immunotherapy for Pancreatic Cancer.Digestive diseases and sciences · 2021Review
- Prognostic value and immunological characteristics of a novel autophagy-related signature in pancreatic cancer.Journal of biosciences · 2021Article
- Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications.Frontiers in cell and developmental biology · 2021Review
- An Immunological Glance on Pancreatic Ductal Adenocarcinoma.International journal of molecular sciences · 2020Review
- TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors.JCI insight · 2020Article
- From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer.Cells · 2020Review
- Genetic landscape of prognostic value in pancreatic ductal adenocarcinoma microenvironment.Annals of translational medicine · 2019Article
- Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma.Clinical and translational medicine · 2019Review
- The Reciprocity between Radiotherapy and Cancer Immunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Review
- Ping-Pong-Tumor and Host in Pancreatic Cancer Progression.Frontiers in oncology · 2019Review
- Therapeutic targeting of the crosstalk between cancer-associated fibroblasts and cancer stem cells.American journal of cancer research · 2019Review
- CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.Journal of translational medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous fundamental or clinical trials of dendritic cell (DC) vaccine against pancreatic ductal adenocarcinoma (PDAC) revealed the burgeoning neoadjuvant immunotherapy. Microarray studies indicated that multiple ingredients of the transfer growth factor beta (TGF-β) pathway were overexpressed in PDAC, which inhibited the intratumoral immune response. To explore whether the DC volume in tumor microenvironment contributes to the differentiation of T cell cohort and test the hypothesis that combining DC vaccine with TGF-β inhibitors will elevate the anti-tumor immune response, we managed to co-culture T cells in vitro with pancreatic cancer cells and DCs in different concentrations, and combine TGF-β blockage with DC vaccine therapy in a murine model of pancreatic cancer. In in vitro studies, we discovered that CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.